文献速递肝病消化道肿瘤与早癌

TACE联合索拉非尼对比单纯TACE治疗不可切除肝细胞癌的随机多中心前瞻性TACTICS试验

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
PubMed 文献 · Gut · 2019-12-04

主要终点PFS(定义为TTUP)在联合组显著延长(25.2 vs 13.5个月,p=0.006),TTUP亦显著延长(26.7 vs 20.6个月,p=0.02),OS因事件数不足未分析。

要点

  • TACE联合索拉非尼较单纯TACE显著延长PFS(25.2 vs 13.5个月,p=0.006)。
  • 联合组TTUP显著延长(26.7 vs 20.6个月,p=0.02)。
  • OS未分析,因仅达到73.6%的OS事件数。

核心结论

  • 在不可切除肝细胞癌患者中,TACE联合索拉非尼较单纯TACE显著改善PFS。
  • 不良事件与既往TACE联合试验一致,未出现非预期毒性。

研究设计与样本

  • 随机、多中心、前瞻性试验,纳入不可切除肝细胞癌患者,联合组80例,单纯TACE组76例。
  • 联合组在首次TACE前2-3周开始索拉非尼400mg每日一次,随后在按需常规TACE期间改为800mg每日一次,直至不可治疗进展(TTUP)。
  • TTUP定义为不可治疗肿瘤进展、暂时性恶化至Child-Pugh C或出现血管侵犯/肝外转移。
  • 主要终点为PFS(定义为TTUP)和OS,采用门控层级检验校正多重性。

主要发现

  • 中位PFS在联合组为25.2个月,单纯TACE组为13.5个月(p=0.006)。
  • 中位TTUP在联合组为26.7个月,单纯TACE组为20.6个月(p=0.02)。
  • 联合组1年和2年OS分别为96.2%和82.7%,单纯TACE组分别为77.2%和64.6%。
  • OS未分析,因仅达到73.6%的OS事件数。

临床怎么用

  • 对于不可切除肝细胞癌,可考虑TACE联合索拉非尼以延长PFS和TTUP。
  • 联合方案需在首次TACE前2-3周开始索拉非尼400mg每日一次,TACE期间改为800mg每日一次。

局限性

  • OS未分析,因仅达到73.6%的OS事件数。
  • PFS采用非传统定义(TTUP),需注意解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE. DESIGN: Patients with unresectable hepatocellular carcinoma (HCC) were randomised to TACE plus sorafenib (n=80) or TACE alone (n=76). Patients in the combination group received sorafenib 400 mg once daily for 2-3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable (unTACEable) progression (TTUP), defined as untreatable tumour progression, transient deterioration to Child-Pugh C or appearance of vascular invasion/extrahepatic spread. Co-primary endpoints were progression-free survival (PFS), which is not a conventional one but defined as TTUP, or time to any cause of death plus overall survival (OS). Multiplicity was adjusted by gatekeeping hierarchical testing. RESULTS: Median PFS was significantly longer in the TACE plus sorafenib than in the TACE alone group (25.2 vs 13.5 months; p=0.006). OS was not analysed because only 73.6% of OS events were reached. Median TTUP (26.7 vs 20.6 months; p=0.02) was also significantly longer in the TACE plus sorafenib group. OS at 1 year and 2 years in TACE plus sorafenib group and TACE alone group were 96.2% and 82.7% and 77.2% and 64.6%, respectively. There were no unexpected toxicities. CONCLUSION: TACE plus sorafenib significantly improved PFS over TACE alone in patients with unresectable HCC. Adverse events were consistent with those of previous TACE combination trials. TRIAL REGISTRATION NUMBER: NCT01217034.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019. PMID: 31801872. doi:10.1136/gutjnl-2019-318934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。